Välimäki J, Airaksinen P J, Tuulonen A
Department of Ophthalmology, University of Oulu, Finland.
Arch Ophthalmol. 1997 Oct;115(10):1253-6. doi: 10.1001/archopht.1997.01100160423005.
To evaluate the outcome of Molteno implantation in secondary glaucoma associated with juvenile rheumatoid arthritis.
Between January 1, 1986, and December 1, 1996, 27 eyes of 19 consecutive patients with secondary glaucoma due to juvenile rheumatoid arthritis received a Molteno implant. The diagnosis of juvenile rheumatoid arthritis was made according to the American Rheumatism Association criteria.
At the end of the follow-up (mean, 40 months; range, 6-116 months), the mean (+/-SD) postoperative intraocular pressure (IOP) (14.4+/-4.3 mm Hg) was statistically significantly lower than the preoperative IOP (38.3+/-5.6 mm Hg) (P<.001). The Snellen visual acuity remained within 1 line of the preoperative level or improved in 23 (85%) of 27 eyes. A successful outcome (defined as a final IOP of > or =6 mm Hg and < or =22 mm Hg, with fewer than or an equal number of antiglaucoma medications as preoperatively) was achieved in 24 (89%) of 27 eyes. Life-table analysis success rates were 95% after 27 months and 90% after 52 months of follow-up. Postoperative complications included flat anterior chamber (3 eyes), tube block by iris or vitreous (3 eyes), cataract (3 eyes), cornea-tube touch (2 eyes), choroidal detachment (1 eye), corneal edema (1 eye), and corneal abrasion (1 eye).
The Molteno implant is useful and well tolerated in controlling IOP in patients with glaucoma secondary to juvenile rheumatoid arthritis.
评估莫尔滕诺植入术治疗青少年类风湿性关节炎相关性继发性青光眼的疗效。
在1986年1月1日至1996年12月1日期间,19例因青少年类风湿性关节炎导致继发性青光眼的连续患者的27只眼接受了莫尔滕诺植入物植入。青少年类风湿性关节炎的诊断依据美国风湿病协会标准做出。
随访结束时(平均40个月;范围6 - 116个月),术后平均(±标准差)眼压(IOP)(14.4±4.3 mmHg)在统计学上显著低于术前眼压(38.3±5.6 mmHg)(P<0.001)。27只眼中有23只(85%)的斯内伦视力保持在术前水平的1行以内或有所提高。27只眼中有24只(89%)取得了成功的结果(定义为最终眼压≥6 mmHg且≤22 mmHg,抗青光眼药物数量少于或等于术前)。生存表分析显示,随访27个月后的成功率为95%,52个月后的成功率为90%。术后并发症包括浅前房(3只眼)、虹膜或玻璃体阻塞引流管(3只眼)、白内障(3只眼)、角膜与引流管接触(2只眼)、脉络膜脱离(1只眼)、角膜水肿(1只眼)和角膜擦伤(1只眼)。
莫尔滕诺植入物在控制青少年类风湿性关节炎相关性继发性青光眼患者的眼压方面有效且耐受性良好。